Cinde Warmington secured the Democratic nomination for Governor of New Hampshire on Tuesday evening after running unopposed in the primary. Warmington, a former member of the New Hampshire Executive Council, will face incumbent Republican Gov. Kelly Ayotte in the general election on Nov. 3.
The nomination marks the second time Warmington has pursued the governor's office. Her campaign has been defined by scrutiny regarding her past legal work for Purdue Pharma, the pharmaceutical company associated with the marketing of OxyContin. The Republican Governors Association (RGA) has characterized this connection as a disqualifying factor for the state's highest office.
What the Left Is Saying
Warmington has addressed the criticism directly in campaign materials, stating that the attacks on her past legal work are unfounded. She emphasized that her role as an attorney in 2001 involved representing patients' access to healthcare prescribed by their doctors, rather than endorsing the company's marketing strategies.
"My dad, who I loved very, very much, struggled with addiction. We did not escape the opioid crisis," Warmington said in a campaign video titled "Setting the Record Straight." She noted that she was assigned the case by a partner and stated, "What I did not know at the time was that Purdue Pharma was engaged in this massive criminal fraud — something that would only be exposed over years of litigation."
In her 2026 campaign, Warmington has focused on affordability and cost-of-living issues, aligning with broader Democratic priorities. She has criticized Gov. Ayotte and Republicans for failing to address rising costs, stating, "The prices of houses, groceries, electricity and property taxes are crushing working families. And Kelly Ayotte is making your life more expensive. I know we can do better."
Warmington's platform includes opposing Trump administration immigration enforcement through ICE, implementing guardrails for data center construction, and preventing investor groups from purchasing housing. She has also appealed to voters across the political spectrum by promising to eliminate state sales and income taxes.
What the Right Is Saying
The Republican Governors Association (RGA) has centered its attacks on Warmington's professional history with Purdue Pharma. The organization argued that her involvement in the opioid epidemic's marketing era renders her unfit for office.
"Based on her role in fueling the opioid epidemic and calling OxyContin a 'miracle drug,' Cinde Warmington is completely disqualified from being governor," the RGA stated in a message to local outlets. The group further asserted, "Warmington chose a payday over protecting New Hampshire families."
Republicans have highlighted the legal outcomes for Purdue Pharma to underscore their criticism. The company faced investigations and lawsuits over claims that it promoted OxyContin as a non-addictive drug while concealing its potential for abuse. In May, the company was required to pay a $7.4 billion settlement as part of legal resolutions.
Gov. Kelly Ayotte, the incumbent, defeated Democratic candidate Joyce Craig in the 2024 election with 53.6% of the vote to Craig's 44.3%. Republicans are leveraging this margin and Ayotte's incumbency to position the race as a referendum on Warmington's past legal associations and her ability to manage state affairs.
What the Numbers Show
In the 2024 Democratic primary, Warmington lost to Joyce Craig with 41.8% of the vote compared to Craig's 47.9%. Craig subsequently lost the general election to Ayotte. This current nomination is Warmington's second attempt at the governorship.
Purdue Pharma agreed to a $7.4 billion settlement in May, following years of litigation regarding the marketing of OxyContin. The settlement resolves multiple claims related to the company's conduct during the early 2000s and beyond.
In the 2024 general election, Gov. Ayotte received 53.6% of the vote, while her Democratic opponent received 44.3%. This 9.3-point margin provides the baseline for current polling and strategic planning in the 2026 race.
Warmington served on the New Hampshire Executive Council representing the 2nd district from 2021 to 2025. Her tenure in this role provides her with recent executive experience in state governance, though her campaign focus has shifted heavily toward her past legal work and current economic messaging.
The Bottom Line
The November general election will feature a direct contest between an incumbent governor with a recent electoral win and a Democratic challenger whose professional history with Purdue Pharma remains a central point of contention. Republicans are focusing their messaging on Warmington's past legal work, while Warmington is prioritizing cost-of-living issues and tax reform.
Voters will decide between Ayotte's record as governor and Warmington's proposal to eliminate sales and income taxes alongside her stance on housing and immigration enforcement. The outcome may signal broader voter sentiment on economic affordability and the lasting impact of the opioid crisis on political trust in New Hampshire.